DDInter211 DDInter1544
A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Biperiden {u} (Compound) resembles {v} (Compound) Oxyphencyclimine
Biperiden {u} (Compound) binds {v} (Gene) CHRNA2
Biperiden {u} (Compound) upregulates {v} (Gene) DFFB
Biperiden {u} (Compound) palliates {v} (Disease) Parkinson's disease
Biperiden {u} (Compound) downregulates {v} (Gene) POLR2I
Biperiden {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methdilazine
Biperiden {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tripelennamine
Biperiden {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Biperiden (Compound) resembles Oxyphencyclimine (Compound)
Biperiden (Compound) binds CHRNA2 (Gene)
Biperiden (Compound) upregulates DFFB (Gene)
Biperiden (Compound) palliates Parkinson's disease (Disease)
Biperiden (Compound) downregulates POLR2I (Gene)
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Biperiden may lead to a major life threatening interaction when taken with Potassium chloride